Oatly Group AB

Oatly Group AB (NASDAQ: OTLY) is a Sweden-based oat milk company. The company’s dairy product portfolio includes milk, ice creams, yogurts, cooking creams, spreads, and on-the-go drinks. OTLY operates in three geographic regions, namely Americas, Asia, and Europe, Middle East, and Africa (EMEA).

Key Highlights

• The company reported a 59.40% rise in revenues to USD 286.20 million during H1FY21 (ended June 30, 2021) compared to USD 179.55 million during H1FY20.
• OTLY reported an increase in net losses to USD 91.45 million during H1FY21 vs. USD 12.96 million during H1FY20, primarily due to a significant increase in Selling, general, and administrative (SGA) expenses.
• It operates in a highly competitive market where pricing pressure exists. As a result, profit margins are anticipated to remain constrained.
• OTLY announced an increase in oat base capacity at its Ogden, Utah facility on August 16, 2021, to accommodate increased customer demand.
• On May 19, 2021, OTLY completed its IPO listing at the price of USD 17.00 per American Depositary Shares (ADS).
• Stock is currently trading below its crucial short-term (50-day) SMA support levels.
• Stock is leaning towards the lower band of the 52-week range of USD 14.87 to USD 29.00.
• OTLY stock price has declined 25.51% in the past three months, compared to a 30.76% decline in the NASDAQ Composite index.

Technical Price Chart (as of September 01, 2021). Analysis by Kalkine

Conclusion: OTLY's stock has fallen 25.12% in the past three months and is trading around its IPO price. Considering the loss-making history, global pricing pressure, uncertain outlook, and technical indicators, we recommend a "Watch" rating on the stock at the closing price of USD 17.83, down 2.14% as of September 01, 2021.

*The reference data in this report has been partly sourced from REFINITIV.

Ocugen, Inc.

Ocugen, Inc. (NASDAQ: OCGN) is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing gene treatments to treat blindness and producing a COVID-19 vaccine.

Key Highlights

• The firm earned no revenue in Q2FY21, and its losses worsened due to rising operational expenses.
• As of June 30, 2021, the company had cash and cash equivalents of USD 115.64 million with total debt of USD 1.67 million.
• On July 15, 2021, OCGN stated that it had started a rolling submission for COVAXIN, a COVID-19 candidate vaccine, co-developing with Bharat Biotech International Ltd. in the US Canadian markets.
• OCGN has been the target of class-action lawsuits filed by several legal firms. The lawsuits claim that the defendants failed to disclose to investors that the information submitted to the US Food and Drug Administration (FDA) was insufficient to warrant an Emergency Use Authorization (EUA).
• Stock is currently trading above its crucial short-term as well as long-term 50-day and 200-day SMA support levels.
• Stock is currently trading in the mid-band of the 52-week range of USD 0.25 to USD 18.77.
• OCGN's stock price has fallen by 20.47% and 28.11% in the past three and six months, respectively.

Technical Price Chart (as of September 01, 2021). Analysis by Kalkine

Conclusion: Considering the absence of revenues, widened losses, macroeconomic uncertainties, recent lawsuits, and technical indicators, we recommend a "Watch" rating on the stock at the closing price of USD 7.52, down 0.92% as of September 01, 2021.

*The reference data in this report has been partly sourced from REFINITIV.

Disclaimer - This report has been issued by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and prepared by Kalkine and its related bodies corporate authorised to provide general financial product advice. Kalkine.com.au and associated pages are published by Kalkine.

Any advice provided in this report is general advice only and does not take into account your objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Statement or other offer document for the securities or other financial products referred to in Kalkine reports. You should obtain a copy of the relevant Product Disclosure Statement, Information Statement or offer document and consider the statement or document before making any decision about whether to acquire the security or product.

You should also seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice in this report or on the Kalkine website. Not all investments are appropriate for all people.

The information in this report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of information contained in its reports, newsletters and websites. All information represents our views at the date of publication and may change without notice.

Kalkine does not guarantee the performance of, or returns on, any investment. To the extent permitted by law, Kalkine excludes all liability for any loss or damage arising from the use of this report, the Kalkine website and any information published on the Kalkine website (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine hereby limits its liability, to the extent permitted by law, to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

On the date of publishing this report (referred to on the Kalkine website), employees and/or associates of Kalkine and its related entities do not hold interests in any of the securities or other financial products covered on the Kalkine website.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.